STOCK TITAN

CymaBay Therapeutics to Report First Quarter of 2022 Financial Results on Thursday, May 12, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced a conference call to discuss its first-quarter financial results for 2022 on May 12, 2022, at 4:30 p.m. ET. The company is focused on developing therapies for liver diseases with significant unmet needs, notably through its lead candidate, seladelpar, which has received various designations from the FDA and EMA. Investors can access the call via phone or a live webcast at the company's investor relations website.

Positive
  • Seladelpar received breakthrough therapy designation from the FDA.
  • Seladelpar has PRIority MEdicines status from the EMA.
  • Orphan drug designation granted in the U.S. and Europe for seladelpar.
Negative
  • None.

NEWARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, May 12, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2022 and to provide a business update.

Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID#13728967. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.

About CymaBay
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), PRIority MEdicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class treatment for people with primary biliary cholangitis (PBC). Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families and communities we serve. To learn more, visit www.cymabay.com and follow us on Twitter and Linkedin.

Public Relations Contact:            

Glenn Silver
Lazar-FINN Partners
(973) 818-8198
Glenn.silver@finnpartners.com

Investor Relations Contact:

Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com


FAQ

What date is CymaBay's conference call about Q1 2022 results?

The conference call is scheduled for May 12, 2022, at 4:30 p.m. ET.

What is the focus of CymaBay Therapeutics?

CymaBay focuses on developing therapies for liver and chronic diseases with high unmet medical needs.

Which drug received breakthrough therapy designation from the FDA?

Seladelpar received breakthrough therapy designation from the FDA.

How can I access the CymaBay conference call?

You can access the call by dialing 877-407-0784 (U.S.) or 201-689-8560 (international) or via the company's investor relations website.

What is the ticker symbol for CymaBay Therapeutics?

The ticker symbol for CymaBay Therapeutics is CBAY.

CymaBay Therapeutics, Inc.

NASDAQ:CBAY

CBAY Rankings

CBAY Latest News

CBAY Stock Data

3.73B
110.08M
0.52%
103.13%
5.1%
Biotechnology
Healthcare
Link
United States
Fremont